Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $89.92 USD
Change Today +0.08 / 0.09%
Volume 3.0M
HSP On Other Exchanges
Symbol
Exchange
New York
Berlin
As of 8:04 PM 08/27/15 All times are local (Market data is delayed by at least 15 minutes).

hospira inc (HSP) Key Developments

Hospira Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Hospira Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported net sales of $1,183.6 million against $1,135.8 million a year ago. Income from operations was $218.6 million against $99.5 million a year ago. Income before income taxes was $206.0 million against $81.1 million a year ago. Net income was $145.1 million against $70.9 million a year ago. Earnings per share diluted were $0.82 against $0.42 per share a year ago. Adjusted net income from operations was $226.9 million against $179.3 million a year ago. Adjusted net income was $150.2 million against $122.1 million a year ago. Adjusted diluted earnings per share were $0.85 against $0.72 per share a year ago. For the six months, the company reported net sales of $2,358.5 million against $2,186.6 million a year ago. Income from operations was $352.0 million against $199.1 million a year ago. Income before income taxes was $327.9 million against $162.2 million a year ago. Net income was $220.7 million against $138.8 million a year ago. Earnings per share diluted were $1.26 against $0.82 per share a year ago. Adjusted net income from operations was $474.1 million against $330.8 million a year ago. Adjusted net income was $320.3 million against $223.8 million a year ago. Adjusted diluted earnings per share were $1.82 against $1.32 per share a year ago. Net cash provided by operating activities was $186.2 million against $175.5 million a year ago. Capital expenditures was $221.4 million against $184.8 million a year ago.

Hospira Launches of Generic Bivalirudin for Injection

Hospira announced that it had obtained U.S. Food and Drug Administration approval for the launch of bivalirudin for injection, a generic version of The Medicines Company's Angiomax. Hospira's bivalirudin for injection is available in a single-dose flip-top vial, which matches the current branded offering available. Additionally, the company plans to launch a differentiated presentation of the 250 mg bivalirudin for injection in Hospira's unique ADD-Vantage vial. Hospira's bivalirudin for injection is a direct thrombin inhibitor indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA); patients undergoing percutaneous coronary intervention (PCI) with provisional use of glycoprotein IIb/IIIa inhibitor (GPI); and patients with, or at risk of, heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis syndrome (HITTS), undergoing PCI. Bivalirudin is intended for use with aspirin.

Hospira Inc. to Report Q2, 2015 Results on Jul 29, 2015

Hospira Inc. announced that they will report Q2, 2015 results at 9:00 AM, Eastern Standard Time on Jul 29, 2015

US Court of Appeals for the Federal Circuit Court Rules against The Medicines Company in its Angiomax Patent Litigation with Hospira, Inc

The Medicines Company has announced that the US Court of Appeals for the Federal Circuit Court has ruled against the company in its Angiomax, or bivalirudin, patent litigation with Hospira Inc. In its ruling on July 8, 2015, the Federal Circuit held that US Patent Nos. 7,582,727 and 7,598,343 are invalid. On March 31, 2014, the US District Court of Delaware found that all of the asserted claims of the '727 patent and the '343 patent covering Angiomax were valid but not infringed by Hospira's ANDA products. The Medicines Company appealed the District Court's claim construction and non-infringement rulings, while Hospira appealed the validity rulings.

Assistance Publique-Hospitaux de Paris Reaches an Agreement with Hospira to Supply the Biosimilar Inflectra

Assistance Publique-Hospitaux de Paris reached an agreement with Hospira to supply the biosimilar Inflectra (infliximab), which is indicated for the treatment of rheumatoid arthritis, Crohn's disease, and psoriasis. It has secured a 45% price discount compared to Remicade. The contract is reported to be worth an estimated USD 6.6 million per annum. The 45% price discount would be less than the 72% price reduction that Norway secured for Remsima, another biosimilar version of Remicade. There is no indication of what pricing level levels where offered by other biosimilar manufacturers in the negotiations with the AP-HP.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HSP:US $89.92 USD +0.08

HSP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cerner Corp $61.44 USD -0.19
Cintas Corp $85.50 USD +1.49
Endo International PLC $79.00 USD +2.62
UCB SA €67.76 EUR +2.58
Zimmer Biomet Holdings Inc $103.41 USD +2.39
View Industry Companies
 

Industry Analysis

HSP

Industry Average

Valuation HSP Industry Range
Price/Earnings 37.6x
Price/Sales 3.3x
Price/Book 4.3x
Price/Cash Flow 37.4x
TEV/Sales 2.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HOSPIRA INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.